RefleXion Announces Executive Appointments

HAYWARD, Calif.--(BUSINESS WIRE)--RefleXion Medical, a theranostic oncology company, today announced the appointment of Steve Schoch as chief financial officer (CFO) and the promotion of Phil Aulson to chief operating officer (COO). Both report to Todd Powell, RefleXion’s president and chief executive officer.

“Steve’s 30-year track record of excellence and diverse background will be a tremendous asset to the RefleXion team,” said Powell. “He brings extensive experience in fundraising, financial infrastructure and operations management – critical components that will help RefleXion transition from an early-stage to a growth-stage commercial company.”

Before joining RefleXion, Schoch served as COO and CFO at FLYR, Inc., a travel technology company, where he restructured global business and financial operations. Previously, he was CFO at 23andMe, where he led a nearly $1 billion equity raise, including the company’s 2021 IPO. His executive tenure also includes roles at Miramax and Amgen. He currently serves as a board member and audit committee chair of Zura Bio, Ltd., a clinical-stage biotechnology company.

Powell also announced Aulson’s promotion to COO, highlighting his contributions during his nine-year tenure at RefleXion. “Phil has been instrumental in developing our first factory, and establishing our manufacturing, operations, customer service and success teams,” said Powell. “He is a proven leader who brings a strong focus on operational execution to RefleXion.”

Aulson joined RefleXion in 2016 as director of new product introduction. His more than 25 years of experience in medical device manufacturing includes leadership roles at Fortune 500 and startup companies. Before joining RefleXion, he held executive and senior management positions at Oraya Therapeutics, Insound Medical, Hansen Medical, Boston Scientific, and Depuy/Johnson & Johnson.

About RefleXion Medical

RefleXion Medical develops and commercializes SCINTIX biology-guided radiotherapy, a groundbreaking treatment that uses a single radiotracer injection to transform cancer cells into real-time biological beacons to control external-beam radiotherapy delivery to single or multiple tumors. SCINTIX therapy is indicated for use in FDG-guided treatment of lung and bone tumors and is being studied for broader indications. In addition, the company offers the RefleXion® X1 system for conventional radiotherapy for all solid tumors. Learn more at https://reflexion.com/.